Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Motor Evoked Potential Recording Success
NCT04608682Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Beijing Tiantan Hospital. Primary endpoint: Success rate of TceMEPs at 5 minutes. Started Aug 2021; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04608682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608682.